Clinical Psychiatry NewsFDA approves second antiamyloid for Alzheimer’s diseaseJanuary 6, 2023Alzheimer's & CognitionNeurologyGeriatrics
Clinical Psychiatry NewsFDA considers regulating CBD productsJanuary 4, 2023NeurologyAlzheimer's & CognitionAddiction MedicineBusiness of Medicine
Clinical Psychiatry NewsFDA puts REMS requirements on hold to ensure continuity of careNovember 8, 2022Schizophrenia & Other Psychotic DisordersBusiness of Medicine
Clinical Psychiatry NewsEighty percent of U.S. maternal deaths are preventable: Study September 20, 2022Diversity in MedicineDepressionMajor Depressive Disorder
Clinical Psychiatry NewsFDA approves ‘rapid-acting’ oral drug for major depressionAugust 22, 2022DepressionMixed TopicsMajor Depressive Disorder
Clinical Psychiatry NewsFDA panel rejects pimavanserin for Alzheimer’s psychosisJune 20, 2022Alzheimer's & CognitionSchizophrenia & Other Psychotic DisordersGeriatricsNeurology
Clinical Psychiatry NewsFDA panel strongly backs protein-based Novavax COVID-19 vaccineJune 8, 2022COVID-19 Updates
Clinical Psychiatry NewsFDA denies petition to disqualify researchers over controversial ketamine studiesJune 6, 2022Mixed Topics
Clinical Psychiatry NewsMany Americans missing an opportunity to prevent dementiaMay 20, 2022Alzheimer's & CognitionNeurology
Clinical Psychiatry NewsFDA clears diagnostic test for early Alzheimer’sMay 5, 2022Alzheimer's & CognitionNeurologyGeriatrics
Clinical Psychiatry NewsFDA okays first sublingual med for agitation in serious mental illnessApril 11, 2022Schizophrenia & Other Psychotic DisordersBipolar Disorder
Clinical Psychiatry NewsFDA clears once-weekly transdermal patch for Alzheimer’sMarch 16, 2022Alzheimer's & CognitionNeurologyGeriatrics
Clinical Psychiatry NewsClozapine interrupted: APA, others seek FDA forum on REMSMarch 7, 2022Schizophrenia & Other Psychotic Disorders
Clinical Psychiatry NewsTwo emerging drugs exacerbating opioid crisisFebruary 7, 2022Addiction MedicineOpioid Resource Center
